QuidelOrtho Corporation (NASDAQ:QDEL) Given Average Rating of “Reduce” by Analysts

QuidelOrtho Corporation (NASDAQ:QDEL) has been assigned an average rating of “Reduce” from the six research firms that are covering the stock, MarketBeat Ratings reports. Two investment analysts have rated the stock with a sell recommendation and four have given a hold recommendation to the company. The average 12-month target price among brokerages that have updated their coverage on the stock in the last year is $12.3750.

Several equities research analysts have issued reports on the company. Jefferies Financial Group reaffirmed a “hold” rating on shares of QuidelOrtho in a research note on Monday. UBS Group reiterated a “neutral” rating and set a $12.00 price objective on shares of QuidelOrtho in a research report on Thursday, May 7th. JPMorgan Chase & Co. raised their price objective on QuidelOrtho from $11.00 to $12.00 and gave the company an “underweight” rating in a report on Wednesday. Wall Street Zen raised QuidelOrtho from a “sell” rating to a “hold” rating in a report on Sunday, June 28th. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of QuidelOrtho in a research report on Tuesday, April 21st.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the business. Global Retirement Partners LLC boosted its stake in shares of QuidelOrtho by 3,691.7% in the 4th quarter. Global Retirement Partners LLC now owns 910 shares of the company’s stock valued at $26,000 after purchasing an additional 886 shares in the last quarter. Camelot Portfolios LLC purchased a new position in QuidelOrtho in the 4th quarter worth $29,000. Hantz Financial Services Inc. raised its position in QuidelOrtho by 50.3% in the 4th quarter. Hantz Financial Services Inc. now owns 1,082 shares of the company’s stock worth $31,000 after purchasing an additional 362 shares during the period. Larson Financial Group LLC lifted its stake in QuidelOrtho by 322.2% in the third quarter. Larson Financial Group LLC now owns 1,330 shares of the company’s stock worth $39,000 after purchasing an additional 1,015 shares during the last quarter. Finally, Leonteq Securities AG lifted its stake in QuidelOrtho by 555.2% in the first quarter. Leonteq Securities AG now owns 3,466 shares of the company’s stock worth $57,000 after purchasing an additional 2,937 shares during the last quarter. 99.00% of the stock is owned by hedge funds and other institutional investors.

QuidelOrtho Stock Performance

NASDAQ QDEL opened at $18.25 on Friday. QuidelOrtho has a 52-week low of $9.92 and a 52-week high of $35.58. The company has a debt-to-equity ratio of 1.33, a quick ratio of 0.80 and a current ratio of 1.43. The company has a market capitalization of $1.24 billion, a P/E ratio of -1.02 and a beta of 0.69. The company has a fifty day moving average of $13.06 and a 200-day moving average of $19.95.

QuidelOrtho (NASDAQ:QDEL) last announced its earnings results on Tuesday, May 5th. The company reported ($0.04) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.37 by ($0.41). The company had revenue of $619.80 million during the quarter, compared to analysts’ expectations of $665.23 million. QuidelOrtho had a positive return on equity of 4.25% and a negative net margin of 45.57%.The firm’s revenue was down 10.5% on a year-over-year basis. During the same quarter last year, the firm posted $0.74 earnings per share. QuidelOrtho has set its FY 2026 guidance at 1.800-2.000 EPS. As a group, equities research analysts predict that QuidelOrtho will post 1.87 EPS for the current fiscal year.

QuidelOrtho Company Profile

QuidelOrtho is a global diagnostics company formed through the merger of Quidel Corporation and Ortho Clinical Diagnostics. The combined entity develops, manufactures and markets a broad portfolio of rapid and high-throughput diagnostic solutions across immunoassay, molecular diagnostics and transfusion medicine. Its offerings span point-of-care platforms for acute care testing as well as large-scale automated systems designed for clinical laboratories and blood banks.

The company’s product range includes rapid antigen and antibody tests for infectious diseases, molecular assays utilizing nucleic acid amplification technology, and integrated immunodiagnostic analyzers.